Sangamo Therapeutics, Inc. (SGMOQ)
0.161
-0.01
(-3.13%)
USD |
OTCM |
Sep 04, 16:00
Sangamo Therapeutics Cash from Investing (Quarterly) : -0.013M for March 31, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | -0.013M |
| December 31, 2025 | -0.014M |
| September 30, 2025 | -0.064M |
| June 30, 2025 | -0.024M |
| March 31, 2025 | 0.00 |
| December 31, 2024 | 1.324M |
| September 30, 2024 | 0.233M |
| June 30, 2024 | 0.127M |
| March 31, 2024 | 35.84M |
| December 31, 2023 | 37.71M |
| September 30, 2023 | 37.63M |
| June 30, 2023 | 42.47M |
| March 31, 2023 | 35.73M |
| December 31, 2022 | 42.61M |
| September 30, 2022 | -13.46M |
| June 30, 2022 | 28.43M |
| March 31, 2022 | 1.705M |
| December 31, 2021 | 52.64M |
| September 30, 2021 | 60.98M |
| June 30, 2021 | 89.30M |
| March 31, 2021 | 45.29M |
| December 31, 2020 | -130.46M |
| September 30, 2020 | -242.50M |
| June 30, 2020 | 77.61M |
| March 31, 2020 | 23.72M |
| Date | Value |
|---|---|
| December 31, 2019 | -16.40M |
| September 30, 2019 | -16.22M |
| June 30, 2019 | -12.38M |
| March 31, 2019 | -14.80M |
| December 31, 2018 | 62.84M |
| September 30, 2018 | 82.77M |
| June 30, 2018 | -312.14M |
| March 31, 2018 | -11.57M |
| December 31, 2017 | 24.47M |
| September 30, 2017 | -27.06M |
| June 30, 2017 | -84.37M |
| March 31, 2017 | 6.059M |
| December 31, 2016 | 6.266M |
| September 30, 2016 | 32.02M |
| June 30, 2016 | -3.861M |
| March 31, 2016 | -16.30M |
| December 31, 2015 | 45.24M |
| September 30, 2015 | 21.96M |
| June 30, 2015 | -8.19M |
| March 31, 2015 | 18.45M |
| December 31, 2014 | -0.319M |
| September 30, 2014 | -83.48M |
| June 30, 2014 | -20.75M |
| March 31, 2014 | 3.887M |
| December 31, 2013 | -68.95M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 43.68M |
| Oncolytics Biotech, Inc. | 0.00 |
| Sarepta Therapeutics, Inc. | -93.37M |
| Anixa Biosciences, Inc. | 0.422M |
| Vicapsys Life Sciences, Inc. | 0.00 |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -19.28M |
| Cash from Financing (Quarterly) | 26.70M |
| Free Cash Flow | -90.46M |
| Free Cash Flow Per Share (Quarterly) | -0.0495 |
| Free Cash Flow to Equity (Quarterly) | -11.83M |
| Free Cash Flow to Firm (Quarterly) | -19.30M |
| Free Cash Flow Yield | -174.4% |